SG11202101807SA - Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one - Google Patents
Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-oneInfo
- Publication number
- SG11202101807SA SG11202101807SA SG11202101807SA SG11202101807SA SG11202101807SA SG 11202101807S A SG11202101807S A SG 11202101807SA SG 11202101807S A SG11202101807S A SG 11202101807SA SG 11202101807S A SG11202101807S A SG 11202101807SA SG 11202101807S A SG11202101807S A SG 11202101807SA
- Authority
- SG
- Singapore
- Prior art keywords
- undecan
- diazaspiro
- improved synthesis
- synthesis
- improved
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/18—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722675P | 2018-08-24 | 2018-08-24 | |
| PCT/US2019/048029 WO2020041770A1 (en) | 2018-08-24 | 2019-08-23 | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101807SA true SG11202101807SA (en) | 2021-03-30 |
Family
ID=69591326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101807SA SG11202101807SA (en) | 2018-08-24 | 2019-08-23 | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11708337B2 (en) |
| EP (1) | EP3840756A4 (en) |
| KR (1) | KR20210049847A (en) |
| CN (1) | CN112839657A (en) |
| AU (1) | AU2019325685A1 (en) |
| SG (1) | SG11202101807SA (en) |
| WO (1) | WO2020041770A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018129387A1 (en) | 2017-01-06 | 2018-07-12 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
| IL298294A (en) | 2020-05-19 | 2023-01-01 | G1 Therapeutics Inc | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| CN112094241B (en) * | 2020-09-19 | 2023-04-18 | 浙江凯普化工有限公司 | Preparation method of 1, 4-diazaspiro [5,5] undecane-3-ketone |
| KR20220143393A (en) | 2021-04-16 | 2022-10-25 | 주식회사 에이치엘클레무브 | Lidar apparatus and control method thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9807305A (en) | 1997-02-05 | 2000-05-02 | Warner Lambert Co | Pyrido [2,3-d] pyrimidines and 4-aminopyrimidines as inhibitors of cell proliferation. |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6506760B1 (en) | 2000-04-14 | 2003-01-14 | Corvas International, Inc. | Substituted hydrazinyl heteroaromatic inhibitors of thrombin |
| OA12292A (en) | 2000-06-26 | 2003-11-11 | Pfizer Prod Inc | PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents. |
| AU2001277032A1 (en) | 2000-08-04 | 2002-02-18 | Warner Lambert Company | 2-(4-pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7 ones |
| KR20060111716A (en) | 2002-01-22 | 2006-10-27 | 워너-램버트 캄파니 엘엘씨 | 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| WO2004047725A2 (en) | 2002-09-11 | 2004-06-10 | Merck & Co. Inc. | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors |
| WO2004065378A1 (en) | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| NZ544609A (en) | 2003-07-11 | 2008-07-31 | Warner Lambert Co | Isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one |
| BRPI0415833A (en) | 2003-10-23 | 2007-01-02 | Hoffmann La Roche | triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders |
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| CN100422183C (en) * | 2004-01-08 | 2008-10-01 | 弗·哈夫曼-拉罗切有限公司 | Diaza-spiropiperidine derivatives as inhibitors of glycine transporter 1 and glycine transporter 2 |
| ITMI20040874A1 (en) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | INDOLIC AND AZAINDOLIC DERIVATIVES WITH ANTI-TUMORAL ACTION |
| WO2006029153A2 (en) | 2004-09-08 | 2006-03-16 | Merck & Co., Inc. | Monocyclic anilide spirolactam cgrp receptor antagonists |
| US8003792B2 (en) | 2004-09-13 | 2011-08-23 | Merck Sharp & Dohme Corp. | Bicyclic anilide spirolactam CGRP receptor antagonists |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| US20060142312A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| EP1846408B1 (en) | 2005-01-14 | 2013-03-20 | Janssen Pharmaceutica NV | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| AU2006316627A1 (en) | 2005-11-18 | 2007-05-31 | Merck Sharp & Dohme Corp. | Spirolactam aryl CGRP receptor antagonists |
| WO2008073251A1 (en) | 2006-12-08 | 2008-06-19 | Merck & Co., Inc. | Constrained spirocyclic compounds as cgrp receptor antagonists |
| WO2008109464A1 (en) | 2007-03-02 | 2008-09-12 | University Of Massachusetts | Spirolactam targeting compounds and related compounds |
| MX2009013897A (en) | 2007-06-25 | 2010-03-30 | Neurogen Corp | Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues. |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| AU2008343932B2 (en) | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| MX2010011591A (en) | 2008-04-22 | 2010-11-09 | Astrazeneca Ab | Substituted pyrimidin-5-carboxamides 281. |
| EP2320903B1 (en) | 2008-07-29 | 2017-01-18 | Nerviano Medical Sciences S.r.l. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| EP2331547B1 (en) | 2008-08-22 | 2014-07-30 | Novartis AG | Pyrrolopyrimidine compounds as cdk inhibitors |
| WO2010039997A2 (en) | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| EP2341906A4 (en) | 2008-10-01 | 2012-06-13 | Univ North Carolina | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
| AU2010248886A1 (en) | 2009-05-13 | 2011-12-01 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| UY33227A (en) | 2010-02-19 | 2011-09-30 | Novartis Ag | PIRROLOPIRIMIDINE COMPOUNDS AS INHIBITORS OF THE CDK4 / 6 |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| CN106008533B (en) | 2010-10-25 | 2018-01-23 | G1治疗公司 | CDK inhibitor |
| US8829102B2 (en) | 2010-10-27 | 2014-09-09 | Cabot Corporation | High loading carbon black masterbatch for pressure pipe applications |
| EP2831080B1 (en) | 2012-03-29 | 2017-03-15 | Francis Xavier Tavares | Lactam kinase inhibitors |
| EP2841417A1 (en) | 2012-04-26 | 2015-03-04 | Francis Xavier Tavares | Synthesis of lactams |
| WO2013169574A2 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam cgrp receptor antagonists |
| HUE046653T2 (en) | 2013-03-15 | 2020-03-30 | G1 Therapeutics Inc | Transient protection of normal cells during chemotherapy |
| EP2983670A4 (en) | 2013-04-08 | 2017-03-08 | Pharmacyclics LLC | Ibrutinib combination therapy |
| US20150031674A1 (en) | 2013-07-26 | 2015-01-29 | Genentech, Inc. | Serine/threonine kinase inhibitors |
| WO2015061407A1 (en) | 2013-10-24 | 2015-04-30 | Francis Xavier Tavares | Process for synthesis of lactams |
| US9481591B1 (en) | 2013-12-16 | 2016-11-01 | Barbara Blake | Device and process to treat and disinfect sewage, food processing wastewater and other biologically contaminated water |
| WO2015161287A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of normal cells during chemotherapy |
| CN105622638B (en) | 2014-10-29 | 2018-10-02 | 广州必贝特医药技术有限公司 | Pyrimidine or pyridopyridine ketone compounds and its preparation method and application |
| KR102445288B1 (en) * | 2016-07-01 | 2022-09-19 | 쥐원 쎄라퓨틱스, 인크. | Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amine |
| AU2018208848A1 (en) * | 2017-01-23 | 2019-07-18 | Pfizer Inc., | Heterocyclic spiro compounds as MAGL inhibitors |
-
2019
- 2019-08-23 WO PCT/US2019/048029 patent/WO2020041770A1/en unknown
- 2019-08-23 KR KR1020217008239A patent/KR20210049847A/en unknown
- 2019-08-23 SG SG11202101807SA patent/SG11202101807SA/en unknown
- 2019-08-23 AU AU2019325685A patent/AU2019325685A1/en active Pending
- 2019-08-23 CN CN201980067524.3A patent/CN112839657A/en active Pending
- 2019-08-23 EP EP19853098.2A patent/EP3840756A4/en active Pending
-
2021
- 2021-02-24 US US17/184,354 patent/US11708337B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3840756A4 (en) | 2022-04-27 |
| US20210179567A1 (en) | 2021-06-17 |
| AU2019325685A1 (en) | 2021-03-18 |
| WO2020041770A1 (en) | 2020-02-27 |
| US11708337B2 (en) | 2023-07-25 |
| KR20210049847A (en) | 2021-05-06 |
| EP3840756A1 (en) | 2021-06-30 |
| CN112839657A (en) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276802A (en) | Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones | |
| IL277072A (en) | Anti-claudin 18.2 antibodies | |
| SG11202101807SA (en) | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one | |
| IL282178A (en) | Products, uses & methods | |
| EP4017883A4 (en) | Novel anti-cldn18.2 antibodies | |
| EP3774027A4 (en) | Electrocatalysts, the preparation thereof, and using the same for ammonia synthesis | |
| EP3846791A4 (en) | Illudin analogs, uses thereof, and methods for synthesizing the same | |
| SG11202006252YA (en) | Hyper-branched compounds, synthesis and uses thereof | |
| IL284765A (en) | 1,8-naphthyridinone compounds and uses thereof | |
| GB201813645D0 (en) | Methods, products & uses relating thereto | |
| GB201813648D0 (en) | Methods, products & uses relating thereto | |
| SG11202108840XA (en) | Producing compositions comprising two or more antibodies. | |
| GB202015822D0 (en) | 66.123.142648/01 | |
| IL277800A (en) | Method for producing 3,4-dichloro-n-(2-cyanophenyl)-5-isothiazolecarboxamide | |
| EP3911656A4 (en) | Synthesis of 14-methyl-16-oxabicyclo[10.3.1]hexadec-12-ene | |
| GB201910389D0 (en) | Novel compounds, methods for their manufacture, and uses thereof | |
| EP3864105A4 (en) | Compositions comprising 2,3,3,3-tetrafluoropropene | |
| GB201715114D0 (en) | 9 (11)-estosterene-16a, 17a-epoxy-3ß-ol-20-one drug intermediates synthesis method | |
| ES2686136B1 (en) | 9,10-BIS SYNTHESIS PROCEDURE (CHLOROME) ANTRACENE | |
| PL3831816T3 (en) | Method for the synthesis of 4,6-dinitrobenzofuroxane | |
| TWI799615B (en) | Novel polyacyloxymethyl-4,4'-acyloxybiphenyl compound | |
| GB201819687D0 (en) | Mrbr.5 | |
| IL289141A (en) | 7,8-dihydro-4h-pyrazolo[4,3-c]azepine-6-one compounds | |
| IL291640A (en) | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease | |
| GB201817509D0 (en) | Products, uses & methods |